New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Check below for free stories on BMY;FB;PMFG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
April 23, 2014
08:15 EDTFBFacebook April weekly volatility elevated at 153 into Q1 and outlook
Subscribe for More Information
07:37 EDTBMYPeregrine announces investigator-sponsored combination trial with Bristol-Myers
Peregrine Pharmaceuticals (PPHM) announced the opening of an investigator-sponsored trial, or IST, of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's (BMY) ipilimumab, for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine, or PS, a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer, as part of the SUNRISE pivotal Phase III clinical trial.
06:16 EDTBMYPharmaceutical companies narrowing focus, WSJ reports
Subscribe for More Information
April 22, 2014
19:03 EDTBMY Bristol-Myers and Samsung BioLogics to increase scope of existing agreement
Subscribe for More Information
16:04 EDTFBOptions Update; April 22, 2014
Subscribe for More Information
14:47 EDTBMYOnglyza, Kombiglyze XR get Paragraph IV patent challenges
Subscribe for More Information
14:22 EDTFBFacebook's WhatsApp says 'half a billion people' now regular users of app
Subscribe for More Information
10:06 EDTFBFacebook rises after Credit Suisse ups rating ahead of earnings
Shares of Facebook (FB) are climbing after Credit Suisse upgraded the stock in a note to investors last night. WHAT'S NEW: Credit Suisse analyst Stephen Ju now expects Facebook to obtain more revenue, on average, from each of its users than the firm had previously anticipated. New products that Facebook is developing should enable the company to obtain more revenue over the medium to long term without boosting its ad loads, the analyst contends. Other analysts are underestimating the amount of revenue that Facebook's new products will generate, added Ju. He upgraded Facebook to Outperform from Neutral and raised his price target on the shares to $87 from $65. WHAT'S NOTABLE: Yesterday research firm JMP Securities increased its first quarter estimates for Facebook, saying that the company's investments are causing advertisers to buy more ads on the website. The firm expects the social network's ad sales to continue to be strong as it launches new types of ads. It reiterated an $82 price target and Outperform rating on the stock. Facebook is expected to report first quarter earnings after the market close on Wednesday, April 23, with a conference call scheduled for 5:00 pm ET. PRICE ACTION: In early trading, Facebook climbed $1.47, or 2.4%, to $62.71.
10:00 EDTFBOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTFBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Netflix (NFLX), up 8%... Harley-Davidson (HOG), up 7%... PLX Technology (PLXT), up 8%... Illinois Tool (ITW), up 2.3%... Comcast (CMCSA), up 1%... McDonald's (MCD), up 0.6%. ALSO HIGHER: Allergan (AGN), up 17% after Valeant (VRX) confirms proposal to combine with the company for $48.30 and 0.83 shares of stock. Valeant is up 5% following its confirmation of the news that broke last night... GlaxoSmithKline (GSK), up 4.5% after agreeing to sell oncology products for $14.5B to Novartis (NVS) and buy Novartis' Vaccines business, currently excluding its flu business, for $7.1B plus royalties. Novartis shares trading in New York are also up 1% following the deals... Revance Therapeutics (RVNC), up 20% after announcing positive results from RT002 Phase 1/2 study... Facebook (FB), up 2% following upgrade at Credit Suisse. DOWN AFTER EARNINGS: Xerox (XRX), down 4%... Lexmark (LXK), down 4.8%. ALSO LOWER: Allison Transmission (ALSN), down 4% after filing to sell 25M shares for holders... FireEye (FEYE), down 2.9% after filing to sell 13.3M shares of common stock for holders... Bebe stores (BEBE), down 16% after reporting preliminary Q3 losses that were steeper than the consensus estimate.
07:24 EDTFBSourceMedia to hold a forum
26th Annual Card Forum & Expo is being held in Orlando on April 22-25.
07:20 EDTFBFacebook volatility elevated into Q1 and outlook
Subscribe for More Information
April 21, 2014
16:35 EDTPMFGPMFG, Inc. awarded two new material orders worth over $9M
Subscribe for More Information
16:32 EDTFBFacebook upgraded to Outperform, price target raised to $87 at Credit Suisse
Subscribe for More Information
16:07 EDTFBFacebook upgraded to Outperform from Neutral at Credit Suisse
13:44 EDTFBFacebook rises after report says mobile ad network coming soon
Subscribe for More Information
11:10 EDTFBFacebook to introduce plans for mobile ad network, Re/code says
Facebook is planning to disclose plans for a for a mobile ad network and will demonstrate the ads to publishers and developers as a way to leverage the company's database of user information for more effective ad targeting, says Re/code. According to sources, Facebook will introduce its plans for its mobile ad network at its “F8″ developer conference at the end of the month, added Re/code. Reference Link
08:59 EDTFBFacebook gives some 'Paper' data, but not users, WSJ says
Facebook disclosed at the end of last week that users of its mobile newsreader app “Paper” view an average of 80 stories a day, but the social network gave no data on how many people have downloaded the app, reported The Wall Street Journal. Reference Link
08:14 EDTFBFacebook Q1 estimates raised ahead of earnings at JMP Securities
Subscribe for More Information
07:21 EDTBMYFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use